Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 Study of Ibrutinib in Combination with Venetoclax in Mantle Cell Lymphoma
2017-000129-12Phase 3Unknown
- Sponsor
- Pharmacyclics
- Start
- Apr 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised trial of ibrutinib and venetoclax in mantle cell lymphoma (MCL), sponsored by Pharmacyclics. Primary endpoints: Safety Run-in Response Rate, Safety Run-in Progression-Free Survival (PFS) and 2 more. Status: unknown.
02
Drugs
ibrutinibvenetoclax
03
Conditions
mantle cell lymphoma (MCL)
Beyond the preview
Go deeper on 2017-000129-12.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-000129-12.